Sharpening the pencil: Rethinking trial design with the patient at the center
New medicines are at the core of clinical research. Historically in clinical research, these experimental medicines move from a warehouse to a…
Lessons Learned
Patient engagement, thinking ahead and how the clinical research industry helps solve global problems: A conversation with Alistair Macdonald – Part 2
In August 2020, Syneos Health CEO Alistair Macdonald reflected on the COVID-19 crisis to date. Read Part 1 of the conversation. In…
Lessons Learned
Clinical Research in the COVID Era: Learning Lessons, Saving Lives
Doug Peddicord, ACRO’s Executive Director, introduces the series and sheds light on the importance of CROs and technology companies in spearheading clinical innovation through COVID-19 and beyond.
Lessons Learned
COVID, the role of digital, and the future of clinical research: A conversation with Alistair Macdonald – Part 1
In August 2020, Syneos Health CEO and ACRO Board Chair Alistair Macdonald reflected on the COVID-19 crisis to date. This conversation has been edited lightly for clarity.
Press Releases
New ACRO Report Introduces Quality-by-Design, Risk-Based Framework for Decentralizing Clinical Trials
September 1, 2020 – (Washington, DC) – Clinical trial activities have traditionally centered around trial sites where patients travel for participation. This…
NewsPress Releases
ACRO Members Heed the UK Government’s Call for Volunteers in Response to the COVID-19 Pandemic
May 6, 2020 – (Washington, DC) – In an effort to fight the global COVID-19 pandemic, over 150 employees from clinical research…
Read More
2020 Officers and New Member Announcement
Washington DC – The Association of Clinical Research Organizations (ACRO) is pleased to announce that its Board of Directors has elected Alistair…
Read More
ACRO hosts Congressional Briefing on clinical research advancements
On Wednesday, October 23, 2019, ACRO hosted a Congressional Briefing on Capitol Hill. With the help of the Congressional Research & Development…
Read More
A Consistent Approach to Risk Based Quality Management: Collaboration is Key
Developing, executing and overseeing clinical trials is a complex process. Yet it is essential to gain reliable evidence from clinical trials to…
Read More
New ACRO Report Quantifies Benefits of RBM for Quality Reviews
A new report based on a survey of ACRO members reveals that Risk-Based Monitoring (RBM) makes clinical trial quality review more efficient…
Read More
Advancing the Adoption of Risk-Based Monitoring Strategies in Clinical Trials
On July 17, 2019, under cooperative agreement with the FDA, the Duke-Margolis Center for Health Policy (Duke Margolis) held a public workshop. The event, titled Improving the Implementation of Risk-Based Monitoring Approaches of Clinical Investigations, aimed to identify opportunities to improve Risk Based Monitoring (RBM) implementation and solicit stakeholder input on the challenges, barriers, and enablers that impact the successful adoption of RBM.
Read More
ACRO offers unique insights on risk-based monitoring of clinical trials, calls for adoption of RBM as a best practice
Following meetings with then-Commissioner Scott Gottlieb and senior leadership from the Center for Drug Evaluation and Research on the role of CROs and technology companies in designing and implementing risk-based monitoring (RBM) of clinical trials, ACRO this week submitted extensive comments on recent FDA Guidance.Increasing the use of innovative RBM technologies helps make clinical trials safer, more efficient and higher quality. ACRO’s comments offer unique insights into the recent expansion of RBM implementation and call for further increasing the use of these oversight technologies.
Read More
ACRO expands membership with addition of three digital technology companies
The Association of Clinical Research Organizations (ACRO) is pleased to announce the expansion of its membership to include ERT, Oracle and Veeva. These new ACRO member companies, with their focus on digital technologies that enable global clinical trials, characterize the ongoing innovation and evolution of contemporary clinical research. ACRO now has 12 member companies.
Read More
ACRO testifies before IRS and Treasury Department on proposed Base Erosion and Anti-Abuse Tax (BEAT) regulation
On Monday, March 25, 2019 ACRO provided testimony at a public hearing held by the Internal Revenue Service (IRS) and Treasury Department…
Read More
EU efforts turn towards digital for 2019
2018 was a busy and productive year for ACRO’s European Scientific & Regulatory Committee, which meets quarterly in London. While the Committee focused largely on the continuing implementation of the EU Clinical Trial Regulation, there were also opportunities to engage with regulators on other topics ranging from European regulatory strategy to Advanced Therapies to the urgent challenges of Brexit.
Read More
Dr. Cynthia Verst of IQVIA Elected 2019 ACRO Chair
Washington DC – The Association of Clinical Research Organizations (ACRO) is pleased to announce that its Board of Directors has elected Dr. Cynthia Verst,…
Read More
UK Government focus on strengthening clinical research amidst unique challenges of Brexit
The Association of Clinical Research Organizations (ACRO) convenes discussion series that seeks to advance an industry with important health and economic impacts…
Read More
ACRO members talk UK competitiveness and enabling post-Brexit success
What happens to clinical research when the UK leaves the EU’s common market and regulatory structure? When public perceptions seem locked onto…
Read More
Who’s in and who’s out? ACRO talks Inclusion-Exclusion Criteria
ACRO joins FDA public meeting to discuss trial risks and rationale, benefits and barriers Clinical trials have an enormous number of inter-related,…
Read More
ACRO Opposes Fatally-Flawed Right-To-Try Legislation
In May of 2017 the Board of Directors of the Association of Clinical Research Organizations, which represents the world’s leading clinical research…